Publications by authors named "Marco Bono"

Claim this Profile
O
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study.
Valerio Gristina, Viviana Bazan, Nadia Barraco, Simona Taverna, Mauro Manno, Marco Bono

Mol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cross-Sectional Study of Variant Interpretation and Reporting of NGS Data Using Tertiary Analysis Software: Navify Mutation Profiler.
Francesco Pepe, Gianluca Russo, Nadia Barraco, Marco Bono, Angela Listì

Oncol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scientific Communication and oncology - "The bridge between knowledge and patients".
Antonio Galvano, Andrea Gottardo, Valerio Gristina, Daniele Fanale, Lidia Rita Corsini, Marco Bono

Crit Rev Oncol Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer.
Andrea Gottardo, Tancredi Didier Bazan Russo, Alessandro Perez, Marco Bono, Emilia Di Giovanni

Cytopathology· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors.
Tancredi Didier Bazan Russo, Clarissa Mujacic, Emilia Di Giovanni, Maria Concetta Vitale, Carla Ferrante Bannera, Marco Bono

Cancer Gene Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors.
Lorena Incorvaia, Tancredi Didier Bazan Russo, Valerio Gristina, Alessandro Perez, Chiara Brando, Marco Bono

NPJ Precis Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
-
-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants?
Daniele Fanale, Lidia Rita Corsini, Chiara Brando, Ugo Randazzo, Marco Bono

Front Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. "Re-discovering the neglected biosources of the liquid biopsy family".
Andrea Gottardo, Valerio Gristina, Alessandro Perez, Emilia Di Giovanni, Silvia Contino, Marco Bono

J Liq Biopsy· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints.
Daniele Fanale, Lidia Rita Corsini, Marco Bono, Ugo Randazzo, Nadia Barraco

Crit Rev Oncol Hematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, Chiara Brando, Valerio Gristina, Marco Bono

Cancer Treat Rev· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay.
Lorena Incorvaia, Gaetana Rinaldi, Giuseppe Badalamenti, Alessandra Cucinella, Chiara Brando, Marco Bono

Ther Adv Med Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study.
Valerio Gristina, Nadia Barraco, Maria La Mantia, Luisa Castellana, Lavinia Insalaco, Marco Bono

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.
Alessandra Dimino, Chiara Brando, Laura Algeri, Valerio Gristina, Erika Pedone, Marco Bono

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
Daniele Fanale, Alessia Pivetti, Daniela Cancelliere, Antonio Spera, Marco Bono

Crit Rev Oncol Hematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Daniele Fanale, Lidia Rita Corsini, Raimondo Scalia, Chiara Brando, Alessandra Cucinella, Marco Bono

Crit Rev Oncol Hematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Not all 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs).
Lorena Incorvaia, Giuseppe Badalamenti, Daniele Fanale, Bruno Vincenzi, Ida De Luca, Marco Bono

Ther Adv Med Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence and Spectrum of Germline and Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.
Daniele Fanale, Alessia Fiorino, Lorena Incorvaia, Alessandra Dimino, Clarissa Filorizzo, Marco Bono

Front Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Risk in Polycythemia Vera: Thrombotic Risk and Survival: Can Cytoreductive Therapy Be Useful in Patients with Low-Risk Polycythemia Vera with Cardiovascular Risk Factors?
Salvatrice Mancuso, Marco Santoro, Vincenzo Accurso, Giuseppe Agliastro, Simona Raso, Marco Bono

Oncol Res Treat· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
pathogenic variants in triple-negative luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients.
Lorena Incorvaia, Daniele Fanale, Marco Bono, Valentina Calò, Alessia Fiorino

Ther Adv Med Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A "Lymphocyte MicroRNA Signature" as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming.
Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Chiara Brando, Marco Bono

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond .
Daniele Fanale, Lorena Incorvaia, Clarissa Filorizzo, Marco Bono, Alessia Fiorino

Cancers (Basel)· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in Genes.
Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Marco Bono, Valentina Calò

Cancers (Basel)· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis.
Antonio Galvano, Marta Castiglia, Sergio Rizzo, Nicola Silvestris, Oronzo Brunetti, Marco Bono

Cancers (Basel)· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Risk in Essential Thrombocythemia and Polycythemia Vera: Thrombotic Risk and Survival.
Vincenzo Accurso, Marco Santoro, Salvatrice Mancuso, Angelo Davide Contrino, Paolo Casimiro, Marco Bono

Mediterr J Hematol Infect Dis· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Lorena Incorvaia, Daniele Fanale, Giuseppe Badalamenti, Nadia Barraco, Marco Bono

Adv Ther· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis